ClinicalTrials.gg
CompletedNCT06677567Updated May 27, 2026

Air-Q and Proseal Laryngeal Mask in Elderly Patients

An interventional study of Air-Q Intubating Airway and proseal laryngeal mask in Postoperative Complications and Sore Throat, sponsored by Diskapi Yildirim Beyazit Education and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Diskapi Yildirim Beyazit Education and Research Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Study summary

Aged- related changes in upper airway anatomy may affect the overall performance of supraglottic airways significantly. In this study, investigator aim to compare the clinical performance, efficacy, and associated complications of the Proseal Laryngeal Mask and the Air-Q Intubation Laryngeal Airway in elderly patients.

Read the detailed description

Elderly patients are vulnerable to perioperative pulmonary complications during intubation and extubation. Supraglottic airway devices (SADs) have been utilized as a relatively easy method of airway management for resuscitation and difficult intubations and are used during elective general anesthesia with reduced airway complications compared to endotracheal intubation. SADs may help maintain hemodynamic stability as they require less anesthetic agents compared to endotracheal intubation. With aging, parapharyngeal fat accumulation increases, leading to pharyngeal collapse in elderly patients. Additionally, structural changes in the respiratory tract combined with physiological alterations in respiration may reduce oxygen saturation, blunt the hypoxic response, and increase postoperative respiratory complications. Acquired changes in pharyngeal muscle activity with age are thought to increase the likelihood of bony structural changes, such as retrognathia, which is typically considered a difficult airway. Therefore, these age-related changes may impact the clinical performance of SADs. ProSeal LMA is one of the most commonly used supraglottic airway devices in clinical practice. It was developed by modifying the classic LMA in the 2000s and features an inflatable cuff. Additionally, it has a gastric channel for gastric aspiration adjacent to the airway tube. Recently, SGAs (supraglottic airways) that do not require manual cuff inflation have been increasingly used in various clinical situations due to the advantages of eliminating manual cuff inflation and monitoring cuff pressure. Air-Q connects to an airway tube via a communication port that allows self-regulation of cuff pressure in response to airway pressure. In this study, investigator aim to compare the clinical performance, efficacy, and associated complications of the Proseal Laryngeal Mask and the Air-Q Intubation Laryngeal Airway in elderly patients.

02

Conditions studied

  • Postoperative Complications
  • Sore Throat

Keywords

  • Air-Q SP Laryngeal İntubating Airway
  • Oropharyngeal leak pressure
  • proseal larygeal mask
  • supraglottic airways
03

In context

Postoperative Complications

1,332 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.

This study's enrollment of 97 is below the median of 114 across 766 interventional studies indexed under Postoperative Complications.

Browse Postoperative Complications studies →

Lead sponsor

Diskapi Yildirim Beyazit Education and Research Hospital is the lead sponsor of 71 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 65-90 year-old patients
  • Physical Status classification I-III,
  • Undergoing an elective operation under general anesthesia in our hospital

Exclusion criteria

Exclusion Criteria:

  • Predicted difficult airway (Mallampati class 4, mouth opening \< 3 cm, or thyromental distance \< 6 cm)
  • (BMI) > 40 kg/m2
  • Patients with a high risk of aspiration (e.g., history of gastrectomy, -gastroesophageal reflux disease, or hiatal hernia),
  • Unstable vital signs
  • Cervical spine problems, Respiratory complications (e.g. recent pneumonia).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
97 participants (actual)

Study arms

  • Other
    SP AİR Q group

    under general anesthesia, patients inserted Air- Q intubating airway.

    Other: Air-Q Intubating Airway

  • Other
    Proseal Group

    under general anesthesia, patients inserted proseal laryngeal mask.

    Other: proseal laryngeal mask

Interventions

  • OtherAir-Q Intubating Airway

    Patients will be inserted Air-Q Intubating Airway under general anesthesia

  • Otherproseal laryngeal mask

    Patients will be inserted proseal laryngeal mask under general anesthesia.

06

What researchers measure

Primary outcomes

  1. Measurement of oropharyngeal leak pressure (OLP)

    One minute after successful LMA placement and fixation, oropharyngeal leak pressure (OLP) will be measured by setting the adjustable pressure limiting valve (APL) to 40 mmHg and maintaining a fresh gas flow of 3 L/min. The OLP will be recorded as the pressure at which an audible leak sound is heard from the mouth.

    Time frame: One minute after successful LMA placement

Secondary outcomes

  1. SP Air-Q and proseal LMA insertion time

    Successful LMA placement will be confirmed by visualizing a square waveform on the ventilator and observing chest wall movement.

    Time frame: 3 minutes after induction of anesthesia

Other outcomes

  1. ease of LMA placement

    he ease of LMA placement will be scored by the anesthesiologist on a scale from 1 to 4 (1: Successful on the first attempt with no resistance from the tissues; 2: Successful on the first attempt but with some tissue resistance during placement; 3: Moderate tissue resistance; 4: Failure to place the LMA).

    Time frame: 3 minutes after induction of anesthesia

  2. maneuvers required for successful ventilation

    It will be recorded whether any further maneuvers are required: Gentle pushing or pulling of the LMA to adjust its depth, jaw-thrust maneuver, and flexion or extension of the head.

    Time frame: 3 minutes after induction of anesthesia

  3. fiberoptic view grading

    The Brimacombe score will be used to evaluate the view obtained with fiberoptic bronchoscopy. 1: Vocal cords are not visible; 2: Vocal cords and anterior epiglottis are visible; 3: Vocal cords and posterior epiglottis are visible; 4: Vocal cords are visible.

    Time frame: 3 minutes after induction of anesthesia

  4. Complications during SP_Air-Q and propseal LMA removal (emerge)

    Complications during SP\_Air-Q and proseal LMA removal (emerge) such as breath-holding during emergence, airway obstruction, coughing, hypoxia (SpO2 \< 90%), vomiting, lip-tongue-teeth trauma, and bleeding, will be recorded.

    Time frame: One minute after SP Air-Q removal

  5. Sore throat

    The presence or absence of sore throat will be recorded at the firsth postoperative hour.

    Time frame: 1 hour postoperatively

  6. Sore throat

    The presence or absence of sore throat will be recorded at the 24th postoperative hour

    Time frame: 24 hours postoperatively

  7. dysphonia

    The presence or absence of dysphonia will be recorded at the firsth postoperative hour

    Time frame: 1 hour postoperatively

  8. dysphonia

    The presence or absence of dysphonia will be recorded at the 24th postoperative hour.

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • Zeynep Koç
    Yenimahalle, Ankara, Turkey (Türkiye)
08

References and documents

Publications

  • Kim EM, Kim MS, Koo BN, Lee JR, Lee YS, Lee JH. Clinical efficacy of the classic laryngeal mask airway in elderly patients: a comparison with young adult patients. Korean J Anesthesiol. 2015 Dec;68(6):568-74. doi: 10.4097/kjae.2015.68.6.568. Epub 2015 Nov 25. PubMed 26634080 ↗
  • In CB, Cho SA, Lee SJ, Sung TY, Cho CK. Comparison of the clinical performance of airway management with the i-gel(R) and laryngeal mask airway SupremeTM in geriatric patients: a prospective and randomized study. Korean J Anesthesiol. 2019 Feb;72(1):39-46. doi: 10.4097/kja.d.18.00121. Epub 2018 Oct 22. PubMed 30343563 ↗
  • Lee JS, Kim DH, Choi SH, Ha SH, Kim S, Kim MS. Prospective, Randomized Comparison of the i-gel and the Self-Pressurized air-Q Intubating Laryngeal Airway in Elderly Anesthetized Patients. Anesth Analg. 2020 Feb;130(2):480-487. doi: 10.1213/ANE.0000000000003849. PubMed 30320644 ↗
  • Wahba RM, Ragaei MZ, Metry AA, Nakhla GM. Supraglottic Airway Devices for Elective Pediatric Anesthesia: I-gel versus Air-Q, Which is the Best? Anesth Essays Res. 2020 Jul-Sep;14(3):461-466. doi: 10.4103/aer.AER_107_20. Epub 2021 Mar 22. PubMed 34092859 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Mar 2025, 4 months.

Of 391 non-industry interventional studies with no phase under Postoperative Complications, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's 4 months is below that.

Counting every sponsor, half of 395 studies reached it within 21 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 6, 2024
StartActual
Nov 10, 2024
Primary completionActual
Mar 10, 2025
CompletionActual
Apr 10, 2025
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06677567
Lead sponsor
Diskapi Yildirim Beyazit Education and Research Hospital
Responsible party
Zeynep Koc (principal investigator, Diskapi Yildirim Beyazit Education and Research Hospital) — Principal investigator
First posted
Nov 6, 2024
Start date
Nov 10, 2024
Primary completion
Mar 10, 2025
Completion
Apr 10, 2025
Last update
May 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion